Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11350817 | 0.88 | CA1 (0.37) | CA1CA2CA4 | |
| SCHEMBL11350814 | 0.88 | CA1 (0.37) | CA1CA2CA4 | |
| SCHEMBL18543689 | 0.88 | CA1 (0.37) | CA1CA2CA4 | |
| SCHEMBL13766711 | 0.86 | CA1 (0.60) | CA1CA2CA4CYP1A2MEN1 | |
| SCHEMBL18543679 | 0.83 | CA1 (0.34) | CA1CA2CA4 | |
| SCHEMBL10771181 | 0.83 | CA1 (0.34) | CA1CA2CA4 | |
| SCHEMBL18543687 | 0.83 | CA1 (0.34) | CA1CA2CA4 | |
| SCHEMBL10771228 | 0.83 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL11591596 | 0.83 | CA1 (0.67) | CA1CA2CA4CYP1A2MEN1 | |
| SCHEMBL18543667 | 0.81 | TDP1 (0.39) | CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | DEYEW BIOTECH CORP. (TW) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | KTN1, TMSB10, TSN | CA1 1618/4885CA2 3544/4885CA4 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.